The Journal of Parkinson’s Disease (JPD), published by IOS Press, has announced the appointment of a new co-Editor-in-Chief, Dr. Lorraine V. Kalia. Dr. Kalia joins co-Editor-in-Chief Dr. Bas Bloem, and an eminent international editorial board, who are dedicated to the continuing success of the world’s leading journal in Parkinson’s research.
A globally recognized authority on Parkinson’s disease, Dr. Lorraine V. Kalia is an Associate Professor and Clinician Scientist in the Division of Neurology at the University of Toronto and a Senior Scientist at the Krembil Research Institute of the University Health Network. She holds appointments with the University of Toronto’s Tanz Centre for Research in Neurodegenerative Diseases and the Department of Laboratory Medicine and Pathobiology. She is also a Staff Neurologist in the Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease at the Toronto Western Hospital, University Health Network.
Dr. Kalia serves as Co-Chair of the Scientific Issues Committee and a Steering Committee Member of the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society. Her clinical work and research program focuses on Parkinson’s disease and related movement disorders. With an eye always on the clinic, she heads a research team focused on elucidating the critical molecular mechanisms responsible for neurodegeneration in Parkinson’s disease and identifying therapeutic agents that can target these molecular mediators of neurodegeneration.
Dr. Kalia’s appointment follows the departure of one of JPD’s founding editors, Dr. Patrik Brundin, who has moved out of academia and is now Therapeutic Area Leader for Movement Disorders at Roche Pharmaceutical Research and Early Development.
The Journal of Parkinson’s Disease (JPD) is dedicated to providing an open forum for original research in basic science, translational research, and clinical medicine that will expedite our fundamental understanding and improve the treatment of Parkinson’s disease. The journal is international and multidisciplinary and aims to promote progress in epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis, and treatment of Parkinson’s disease. It publishes research reports, reviews, short communications, and letters-to-the-editor and offers very rapid publication and an affordable open access option.
Click here to read the original press release.
